Revised forecast
Fiscal year ending March 2026 · Full yearPrevious forecast published 12 May 2025The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
The primary reason was the recognition by the bank on a non-consolidated basis of gains on the sale of shares and other securities in connection with the sale of shares in Hisamitsu Pharmaceutical Co., Inc. The forecasts for ordinary profit and net income remain unchanged from the previous forecasts due to the impact of realizing unrealized losses associated with the restructuring of the securities portfolio funded by gains on the sale of shares and other securities, among other factors.
| Item | Details |
|---|---|
| Net Sales | ¥56,000 million → ¥71,000 million（+26.7%） |
| Ordinary income | ¥11,500 million → ¥11,500 million |
| Profit attributable to owners of the parent | ¥8,000 million → ¥8,000 million |
| Net income per share | 473.63 yen and sen → 473.32 yen and sen |
| Fiscal Period Covered | Fiscal year ending March 2026 |
| Period Covered | Full year |
| Publication date of previous forecast | 12 May 2025 |
| Previous-period results | Consolidated: ordinary income of ¥55,231 million, ordinary profit of ¥11,001 million, net income attributable to owners of the parent of ¥7,496 million, and earnings per share of ¥444.35. Non-consolidated: ordinary income of ¥46,858 million, ordinary profit of ¥10,140 million, net income of ¥6,932 million, and earnings per share of ¥410.94. |
| Reason for the revision | The primary reason was the recognition by the bank on a non-consolidated basis of gains on the sale of shares and other securities in connection with the sale of shares in Hisamitsu Pharmaceutical Co., Inc. The forecasts for ordinary profit and net income remain unchanged from the previous forecasts due to the impact of realizing unrealized losses associated with the restructuring of the securities portfolio funded by gains on the sale of shares and other securities, among other factors. |
| Dividend forecast revision | The year-end dividend will be increased by ¥10 per share, from ¥50.00 to ¥60.00. The annual dividend forecast has been revised from ¥100.00 to ¥110.00 per share. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (2)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The primary reason for the upward revision to the earnings forecasts is the recognition of gains on the sale of shares and other securities in connection with the sale of shares in Hisamitsu Pharmaceutical Co., Inc. The forecasts for ordinary profit and net income remain unchanged, mainly due to the impact of realizing unrealized losses associated with the restructuring of the securities portfolio. The dividend was increased after comprehensively considering the policy of stable dividends, recent earnings trends and the equity ratio.